{"nctId":"NCT04082364","briefTitle":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","startDateStruct":{"date":"2019-09-30","type":"ACTUAL"},"conditions":["Gastric Cancer","Gastroesophageal Junction Cancer","HER2-positive Gastric Cancer"],"count":82,"armGroups":[{"label":"Chemotherapy-free arm","type":"EXPERIMENTAL","interventionNames":["Biological: margetuximab","Biological: Retifanlimab"]},{"label":"Margetuximab, retifanlimab, and chemotherapy arm","type":"EXPERIMENTAL","interventionNames":["Biological: margetuximab","Biological: Retifanlimab","Other: Chemotherapy"]},{"label":"Margetuximab, tebotelimab and chemotherapy arm","type":"EXPERIMENTAL","interventionNames":["Biological: margetuximab","Biological: Tebotelimab","Other: Chemotherapy"]},{"label":"Margetuximab and chemotherapy arm","type":"EXPERIMENTAL","interventionNames":["Biological: margetuximab","Other: Chemotherapy"]},{"label":"Trastuzumab and chemotherapy arm","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Trastuzumab","Other: Chemotherapy"]}],"interventions":[{"name":"margetuximab","otherNames":["MGAH22","Margenza®"]},{"name":"Retifanlimab","otherNames":["MGA012","INCMGA00012"]},{"name":"Tebotelimab","otherNames":["MGD013"]},{"name":"Trastuzumab","otherNames":["Herceptin"]},{"name":"Chemotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Histologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2+ GC or GEJ adenocarcinoma\n\n  1. Prior systemic perioperative treatment is allowed; however the participants must have had a disease-free interval of at least 6 months from end of chemo/surgery\n  2. Participants receiving perioperative anti-HER2 therapy require testing of HER2 status for eligibility\n  3. Cohort A: HER2-positive (by IHC 3+) and PD-L1-positive (by IHC with 22C3 CPS ≥ 1%) per central review\n  4. Cohort B: HER2-positive (by IHC 3+ or IHC 2+ in combination with FISH+) by local review. PD -L1 status is not required for enrollment.\n* Availability of formalin-fixed, paraffin-embedded tumor specimen, unstained slides or contemporaneous biopsy for tumor target testing\n* Eastern Cooperative Oncology Group performance status of 0 or 1, verified within 3 days of Day 1\n* Life expectancy ≥ 6 months\n* At least one radiographically measurable target lesion\n* Acceptable laboratory parameters and adequate organ function\n\nKey Exclusion Criteria:\n\n* Other malignancy that is progressing or required treatment within the past 5 years, with certain exceptions\n\n  * Participants with known MSI-H status\n* History of allogeneic stem cell or tissue/solid organ transplant\n* Central nervous system metastases\n* Clinically significant cardiovascular disease, gastrointestinal disorders, pulmonary compromise\n\n  * Prior neoadjuvant or adjuvant treatment with immunotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0","description":"Evaluation of adverse events and serious adverse events (Cohort A)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology Reviews","description":"Percent of non MSI-H participants with best overall response of complete response (CR) plus partial response (PR) per RECIST 1.1 (Cohorts A ) based on investigator assessment.\n\nCR is defined as the disappearance of all target and non-target lesions with no new lesions appearing PR is defined as \\>= to a 30% decrease in the sum of the longest dimensions of target lesions, non-progression of non- target lesions, with no new lesions appearing.\n\nCR + PR = ORR","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Progression-free Survival Using Investigator-assessed Radiology Reviews in Cohort A","description":"Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first. (Cohorts A) based on investigator assessment","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Duration of Response in Cohort A Using Investigator-assessed Radiology Reviews","description":"Time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first (Cohorts A)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment (Cohorts A and B)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"ORR for Cohort B","description":"Proportion of participants with best overall response of CR plus PR per RECIST 1.1","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"83.3","spread":null},{"groupId":"OG003","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Have Antidrug Antibodies (ADA) to Margetuximab","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Have ADA to Retifanlimab","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Have ADA to Tebotelimab","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":48},"commonTop":["Anaemia","Diarrhoea","Platelet count decreased","Neutrophil count decreased","Nausea"]}}}